TD Cowen raised the firm’s price target on Amgen to $381 from $360 and keeps a Buy rating on the shares. The firm said Q2 EPS were in line with solid sales beats by Prolia, Evenity, Tezspire, Uplizna, and Tavneos.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- AMGN Earnings: Amgen Stock Down on Mixed Q2 Results
- AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
- Options Volatility and Implied Earnings Moves Today, August 06, 2024
- Amgen granted orphan status for pancreatic cancer treatment
- Options Volatility and Implied Earnings Moves This Week, August 05 – August 09, 2024
Questions or Comments about the article? Write to editor@tipranks.com